Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

15987.2;3 PFLS-LS

Projekttitel

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Projekttitel Englisch

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders
Abstract (Englisch)	The project objective is the design, synthesis and pharmacological characterization of a series of novel compounds that are potent and selective inverse agonists of the ghrelin receptor. Ghrelin antagonism/inverse agonism is considered a valid treatment paradigm for obesity, type 2 diabetes and metabolic syndrome. The ultimate goal is to obtain preclinical candidates that could lead to the development of innovative medicines for these pathological conditions.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Abstract
(Englisch)

The project objective is the design, synthesis and pharmacological characterization of a series of novel compounds that are potent and selective inverse agonists of the ghrelin receptor. Ghrelin antagonism/inverse agonism is considered a valid treatment paradigm for obesity, type 2 diabetes and metabolic syndrome. The ultimate goal is to obtain preclinical candidates that could lead to the development of innovative medicines for these pathological conditions.